Jan 23 2015
BIND Therapeutics, Inc., a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins™, today announced the publication of an article in the Journal of the American Medical Association (JAMA) co-authored by Robert S. Langer, Sc.D, David H. Koch Institute Professor, Massachusetts Institute of Technology, co-founder and member of the Board of Directors of BIND and one of seven individuals to have received both the United States National Medal of Science and the United States National Medal of Technology and Innovation.
In the article, titled “Science and Medicine: Nanotechnology,” Dr. Langer provides his vision of therapeutic improvements that may be possible with drug-containing nanoparticles, including the ability to provide potent doses of cancer-killing agents to cancer cells while reducing off-target toxicities.
Source: http://www.bindtherapeutics.com/